Intent to Grant an Exclusive License for U.S. Government-Owned Invention

Name of License: 
Intent to Grant an Exclusive License for U.S. Government-Owned Invention
By the: 
U.S. Army Medical Research & Development Command - Medical Technology Transfer Office (MTT)
On: 
May 11, 2022
Summary 

SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license.

Tech Name: 
U.S. Government-Owned Invention
Action: 
Intent
Dates: 
Anyone wishing to object to grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Director, Office of Research and Technology Applications
Address: 
Commander, U.S. Army Medical Research and Development Command (USAMRDC), ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite 227, Fort Detrick, MD 21702-5012.
For further information contact 

Dr. Paul Michaels, Office of Research & Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory Patent Attorney, (301) 619-7808.

Supplementary information 

SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209 (e) and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive within a field of use, royalty-bearing, revocable license to Celdara Medical, LLC, having its principle place of business at 16 Cavendish Ct. Lebanon, NH 03766. The license agreement includes following U.S. Patents and U.S. Patent Applications:
 U.S. Patent No. 9,346,875 for an invention titled “Therapy for Filovirus Infection” co-owned with the Albert Einstein College of Medicine; and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10;
 U.S. Patent No. 10,081,669; for an invention titled “Therapy for Filovirus Infection” co-owned with the Albert Einstein College of Medicine; and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10;
 U.S. Patent No. 10,435,461; for an invention titled “Therapy for Filovirus Infection” co-owned with the Albert Einstein College of Medicine; and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10;
 U.S. Patent No. 10,875,907 for an invention titled “Filovirus Antibody” co-owned with the Albert Einstein College of Medicine and The Governing Council of the University of Toronto, USAMRDC Reference Number 15-10; and
 U.S. Patent Application No. 17/611,391 for an invention titled “Antibodies to Sudan and Ebola Virus” co-owned with the French Ministry of Defense, USAMRDC Reference Number 18-16.

Correction: 
Upload PDF: 
PDF icon flc_business_notice_usamrdc_11may2022.pdf